Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05119296 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Name: Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer — clinical trial record (NCT05119296)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorSaad A Khan

Started2022-02-15

View on ClinicalTrials.gov ↗

This is a single-arm, open-label trial designed to evaluate the activity of pembrolizumab therapy in anaplastic thyroid cancer in patients with no curative alternative therapy. Pembrolizumab (Keytruda-Merck) 200 mg, given IV every 3 weeks, until evidence of progression, intolerance of treatment, withdrawal of consent or death

Amendment history 5 changes detected by DataLookout

2026-09-10

Enrollment reduced: 12 → 9 participants

2026-09-10

Sponsor changed: Stanford University → Saad A Khan

Was~~Stanford~~ ~~University~~

NowSaad A Khan

2026-09-10

Completion pushed: 2026-09-01 → 2027-07

2026-09-10

Results posted: 2026-09-09

2026-09-10

Interventions modified

Trial Details

NCT Number	NCT05119296
Lead Sponsor	Saad A Khan Collaborators: Merck Sharp & Dohme LLC
Conditions	Thyroid Cancer
Enrollment	9 participants
Start Date	2022-02-15
Primary Completion	2025-05-16 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2026-09-09